China’s Jiangsu Hengrui Tops Global Clinical Trials as China Leads Growth
Creatrip Team
4 months ago
Global clinical trials reached 10,503 new studies last year, a 5.5% increase from 2023. Company-sponsored trials numbered 7,048. China continued to dominate, launching 5,075 trials (up 10%), accounting for over 80% of Asian activity and outpacing the U.S. (2,758). Jiangsu Hengrui Pharmaceuticals (항서제약) became the top company by new trials with 132 starts, moving from fifth to first and running over 400 trials overall, including more than 20 international studies. Hengrui also made major licensing deals this year with Merck (U.S.) and GSK (U.K.). Several traditional leaders—Roche, BMS, and Novartis—fell out of the top 10, while Chinese firms (Hengrui, Sinovac Biopharm, CSPC) and others like GSK and Boehringer Ingelheim entered the top ranks. (항서제약: Jiangsu Hengrui Pharmaceuticals)
